1172.86  -3.24 (-0.28%)		08-28 16:00
Open: 1172.66 High: 1180 Volume: 2,446,017		Pre. Close: 1176.1 Low: 1162.93 Market Cap: 1,104,530(M)

Short term
Mid term
Targets	6-month :	1427.23	1-year :	1509.81
Resists	First :	1221.94	Second :	1292.65
Pivot price	1217.24
Supports	First :	1107.56	Second :	921.49
MAs	MA(5) :	1204.17	MA(20) :	1201.74
	MA(100) :	1095.69	MA(250) :	1005.29
MACD	MACD :	7.7	Signal :	14.3
%K %D	K(14,3) :	14.4	D(3) :	33.4
RSI	RSI(14): 45.4
52-week	High :	1292.65	Low :	707.58

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ LLY ] has closed above bottom band by 15.3%. Bollinger Bands are 5.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	1187.51 - 1198.91	1198.91 - 1205.8
Low:	1138.36 - 1153.48	1153.48 - 1162.62
Close:	1156.66 - 1181.21	1181.21 - 1196.06

Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, HER2- metastatic breast cancer, node-positive, and early breast cancer. For autoimmune and inflammatory conditions, the company markets Olumiant for rheumatoid arthritis, and Taltz, which addresses plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Addressing neurological and pain management needs, Eli Lilly provides Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is available for migraine prevention and episodic cluster headaches, while Zyprexa treats schizophrenia, bipolar I disorder, and aids in bipolar maintenance. Other significant products include Bamlanivimab and etesevimab, along with Bebtelovimab, both developed for COVID-19. Cialis is offered for erectile dysfunction and benign prostatic hyperplasia, and Forteo is available for osteoporosis. Eli Lilly actively engages in strategic collaborations with numerous partners, including Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Established in 1876, Eli Lilly and Company maintains its corporate headquarters in Indianapolis, Indiana.

Fri, 28 Aug 2026
Is OmniAb (OABI)’s Eli Lilly (LLY) Partnership a Game Changer for OABI? - Yahoo Finance

Fri, 28 Aug 2026
Lilly Mounjaro approved to cut cardiovascular risk (LLY:NYSE) - Seeking Alpha

Thu, 27 Aug 2026
Eli Lilly Stock (LLY) Pulls Back After Hitting Record High - TipRanks

Thu, 27 Aug 2026
Eli Lilly Stock Pulls Back After Hitting Record Highs Last Week - Sahm

Wed, 26 Aug 2026
Is Eli Lilly and Co (LLY) a Bargain After 3.6% Drop? GF Value Sa - GuruFocus

Wed, 26 Aug 2026
Eli Lilly Stock Pulls Back After Hitting Record Highs Last Week - Benzinga

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Outperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NYSE
Sector: Healthcare
Industry: Drug Manufacturers - General
Shares Out	0 (M)
Shares Float	892 (M)
Held by Insiders	8.8895e+008 (%)
Held by Institutions	0.1 (%)
Shares Short	9,350 (K)
Shares Short P.Month	0 (K)

EPS	4.171e+010
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	26.2
Profit Margin	1.5 %
Operating Margin	33.5 %
Return on Assets (ttm)	54.2 %
Return on Equity (ttm)	20.3 %
Qtrly Rev. Growth	7.967e+010 %
Gross Profit (p.s.)	93.52
Sales Per Share	200.56
EBITDA (p.s.)	1.30275e+011
Qtrly Earnings Growth	29.7 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	28,080 (M)

PE Ratio	0
PEG Ratio	26.5
Price to Book value	44.8
Price to Sales	5.85
Price to Cash Flow	15.75

Dividend	0
Forward Dividend	9.12e+006
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.